GET DAILY SIGNALSOpus Genetics (IRD): A Closer Look at This Gene Therapy Company Targeting Retinal Diseases
Key Takeaways
- IRD is the Nasdaq ticker for Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company.
- The company develops gene therapies for inherited retinal diseases (IRDs) and other vision-related disorders.
- Opus Genetics was formed through an all-stock combination with Ocuphire Pharma completed in late 2024, with the ticker "IRD" referencing inherited retinal diseases.
- Its lead programs, OPGx-LCA5 and OPGx-BEST1, are in clinical development, supported by a broader preclinical pipeline.
- As a clinical-stage company, Opus Genetics generates limited revenue and remains dependent on research and development milestones and financing.
Getting Started with Opus Genetics
Opus Genetics, Inc. (IRD) is a clinical-stage ophthalmic biopharmaceutical company focused on developing gene therapies intended to restore vision and prevent blindness in patients with inherited retinal diseases, or IRDs, as well as other ophthalmologic conditions. Investors follow the company because it operates in the emerging field of ocular gene therapy, an area that has produced several high-profile, one-time treatments and attracted significant attention for its potential to address diseases with few or no existing options. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Background and Formation
Opus Genetics is headquartered in Durham, North Carolina, in the Research Triangle region. The company traces its roots to a spinout launched in 2021 by the Retinal Degeneration (RD) Fund, the venture arm of the Foundation Fighting Blindness, to develop gene therapies for inherited retinal diseases. Its scientific co-founders include Jean Bennett, M.D., Ph.D., a pioneer in ocular gene therapy who was also a scientific founder of Spark Therapeutics.
The current public entity was formed through an all-stock transaction announced in October 2024, in which Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company, acquired the private Opus Genetics. The combined company adopted the Opus Genetics name and began trading on the Nasdaq under the ticker IRD. Prior corporate predecessors include Ocuphire Pharma and Rexahn Pharmaceuticals.
Pipeline and Business Approach
Opus Genetics operates a single business segment focused on developing products related to vision performance and health. As a clinical-stage company, it does not yet generate meaningful product revenue; its limited revenue has come primarily from license and collaboration agreements. The company funds operations through equity financings and partnerships while advancing its drug candidates through clinical trials.
The company's pipeline is built around adeno-associated virus (AAV)-based gene therapies, which use engineered viral vectors to deliver corrective genes into retinal cells. Its most advanced programs include OPGx-LCA5, a gene therapy for LCA5-associated IRD that has received both Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA, and OPGx-BEST1, targeting IRDs associated with mutations in the BEST1 gene. The company also maintains several earlier-stage, preclinical gene therapy programs targeting genes such as RHO, CNGB1, RDH12, NMNAT1, and MERTK. Beyond gene therapy, Opus Genetics retains interests in a phentolamine ophthalmic solution partnered with Viatris and a small-molecule program for diabetic retinopathy.
Why This Name Draws Investor Attention
Opus Genetics attracts attention for its positioning in the ocular gene therapy field, which offers the possibility of one-time treatments for patients who currently have no approved alternatives. Inherited retinal diseases are a genetically diverse group of rare conditions, and the company's multi-program pipeline aims to address several distinct genetic mutations. A key strategic advantage is the leadership team's deep experience in ophthalmic drug development and the involvement of recognized scientific founders in the gene therapy space. From what I see, clinical milestones such as data readouts from Phase 1/2 and registrational trials remain central to how the story unfolds.
Key Risks to Keep in Mind
Investing in Opus Genetics carries risks typical of early-stage biotechnology companies. As a clinical-stage business, it has limited revenue and has reported net losses, meaning its operations depend on successful fundraising, partnerships, and future regulatory approvals. Drug development is inherently uncertain, and its lead candidates must still demonstrate safety and efficacy in larger trials before any potential approval. Additional considerations include competition from larger, better-capitalized companies pursuing ocular gene therapy, the complexity of manufacturing AAV-based therapies, regulatory risk, and the small patient populations associated with rare genetic diseases.
Using Tickeron Tools in My Research
I’ve been using Tickeron’s AI Screener to screen for biotech opportunities like this one. It lets me filter by industry, signals, and more, helping spot names that fit my criteria without spending hours on manual research. It’s become a go-to in my workflow for early-stage companies in fields like gene therapy.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IRD in +1.20% Uptrend, growing for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IRD advanced for three days, in 215 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IRD's RSI Oscillator exited the oversold zone, 18 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on IRD as a result. In 89 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for IRD just turned positive on November 03, 2026. Looking at past instances where IRD's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
IRD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
IRD moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IRD crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for IRD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-26.779) is normal, around the industry mean (3.498). P/E Ratio (-3.240) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (46.083) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. IRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics
Industry Biotechnology
Advertisement